Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 5/20 | 0.48 |
| ▸ | CTSB | P07858 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16616259 | 1.00 | CAPN1 (0.49) | CAPN1MAOBCTSLCTSBTDP1 | |
| SCHEMBL16616371 | 0.92 | MAOB (0.49) | MAOBABCG2ABCB1RELAMAPT | |
| SCHEMBL16616374 | 0.92 | MAOB (0.49) | MAOBABCG2ABCB1RELAMAPT | |
| SCHEMBL16616463 | 0.92 | ABCG2 (0.47) | MAOBABCG2ABCB1NR1H4RELA | |
| SCHEMBL16616464 | 0.92 | ABCG2 (0.47) | MAOBABCG2ABCB1NR1H4RELA | |
| SCHEMBL16616113 | 0.91 | MAPT (0.50) | CTSLCTSBABCG2ABCB1DPP4 | |
| SCHEMBL16616111 | 0.91 | MAPT (0.50) | CTSLCTSBABCG2ABCB1DPP4 | |
| SCHEMBL16616566 | 0.91 | RELA (0.51) | CTSLCTSBABCG2ABCB1RELA | |
| SCHEMBL16616563 | 0.91 | RELA (0.51) | CTSLCTSBABCG2ABCB1RELA | |
| SCHEMBL16616284 | 0.91 | ABCG2 (0.49) | ABCG2ABCB1RELAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006451-B1 | 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20150099888-A1 | 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099888-A1 | 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof | HCCS, WEE2, WEE1 | CAPN1 3539/4885MAOB 2125/4885CTSL 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.